BONSITY: The new name for Alvogen’s Teriparatide Injection 620 mcg/2.48 mL; same affordable alternative to FORTEO® (teriparatide injection)
For US Healthcare Professionals Only
BONSITY teriparatide injection logo

The new name for Alvogen’s Teriparatide Injection 620 mcg/2.48 mL

Request a Rep
Woman with long silver hair wearing a button-up shirt with her arms folded across her chest

Savings & Resources

Built on affordability

BONSITY is an affordable alternative to FORTEO® (teriparatide injection).*

*Not automatically substituted for FORTEO.
Actor portrayal.
79%

of Medicare Part D lives have access to BONSITY.1

$0

copay for eligible, commercially insured patients.†

Help your patients save on BONSITY

Copay as little as $0 for eligible, commercially insured patients.† Download the BONSITY Savings Program copay card to get started.

Download savings card
BONSITY Savings Program copay card
Select dispense as written when prescribing BONSITY to ensure your patients receive this trusted treatment.

Help your patients get started with BONSITY

Educate your patients with osteoporosis on how BONSITY can help keep them moving while building new bone.2

BONSITY Savings Program Terms and Conditions

Eligible patients can pay as little as $0 and receive up to $12,000 off the patient's co-pay or out of pocket expenses annually of BONSITY (teriparatide injection). Maximum monthly benefit applies. A valid Prescriber ID# is required on the prescription.

Patient Instructions: In order to redeem this offer you must have a valid prescription for BONSITY (teriparatide injection). Follow the dosage instructions given by the doctor. This offer may not be redeemed for cash. By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described in the Restrictions section below. Patients with questions about this offer should call
833-330-0806.

Pharmacist instructions for a patient with an Eligible Third Party: Submit the claim to the primary Third Party Payer first, then submit the balance due to CHANGE HEALTHCARE as a Secondary Payer COB [coordination of benefits] with patient responsibility amount and a valid Other Coverage Code, (e.g., 8). The patient is responsible for the first $0 and the card pays up to the next $12,000. Reimbursement will be received from CHANGE HEALTHCARE. Valid Other Coverage Code required. For any questions regarding Change Healthcare online processing, please call the Help Desk at 800-433-4893.

Pharmacist: When you apply this offer, you are certifying that you have not submitted a claim for reimbursement under any federal, state, or other governmental programs for this prescription. Participation in this program must comply with all applicable laws and regulations as a pharmacy provider. By participating in this program, you are certifying that you will comply with the terms and conditions described in the Restrictions section.

Restrictions:

  • This offer is valid in the United States.
  • Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, Tricare or other federal or state health programs (such as medical assistance programs).
  • Cash Discount Cards and other non-insurance plans are not valid as primary under this offer.
  • If the patient is eligible for drug benefits under any such program, the patient cannot use this offer.
  • It is illegal to (or offer to) sell, purchase, or trade this offer.
  • Not valid if reproduced.
  • By using this offer, the patient certifies that he or she will comply with any terms of his or her health insurance contract requiring notification to his or her payor of the existence and/or value of this offer.
  • This offer is not transferable and is limited to one offer per person.
  • Void where prohibited by law.
  • Program managed by ConnectiveRx on behalf of Alvogen, Inc.
  • The parties reserve the right to rescind, revoke or amend this offer without notice at any time.

Proven efficacy and safety

BONSITY builds on more than 20 years of clinical experience.

See the data

Trusted treatment for osteoporosis

BONSITY is the first FDA-approved teriparatide alternative to FORTEO.‡

Meet BONSITY
‡Not automatically substituted for FORTEO.

Questions about BONSITY?

Connect with a representative to help your patients build new bone with BONSITY

Request a representative
Request
a Rep

Important Safety Information

Indications for use

BONSITY is indicated:

  • For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, BONSITY reduces the risk of vertebral and nonvertebral fractures.
  • To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.
  • For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.

Contraindications

BONSITY is contraindicated in patients with hypersensitivity to teriparatide or to any of its excipients. Reactions have included angioedema and anaphylaxis.

Warnings and Precautions

Osteosarcoma: An increased incidence of osteosarcoma was observed in male and female rats treated with BONSITY. Osteosarcoma has been reported in patients treated with BONSITY in the post marketing setting. There are limited data assessing the risk of osteosarcoma beyond 2 years of BONSITY use. Avoid use in patients with: open epiphyses; metabolic bone diseases including Paget's disease of the bone; bone metastases or history of skeletal malignancies; prior external beam or implant radiation therapy involving the skeleton; and hereditary disorders predisposing to osteosarcoma.

Hypercalcemia and Cutaneous Calcification: BONSITY may cause hypercalcemia and may exacerbate hypercalcemia. Avoid BONSITY in patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism.

Serious reports of calciphylaxis and worsening of previously stable cutaneous calcification have been reported in patients taking BONSITY. Risk factors include underlying autoimmune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. Discontinue in patients developing calciphylaxis or worsening of previously stable cutaneous calcification.

Risk of Urolithiasis: BONSITY has not been studied in patients with active urolithiasis. If BONSITY-treated patients have pre-existing hypercalciuria or suspected/known active urolithiasis, consider measuring urinary calcium excretion. Consider the risks and benefits in patients with active or recent urolithiasis because of risk of exacerbation.

Orthostatic Hypotension: BONSITY should be administered initially under circumstances in which the patient can sit or lie down if symptoms of orthostatic hypotension occur.

Risk of Digoxin Toxicity: Hypercalcemia may predispose patients to digitalis toxicity because BONSITY transiently increases serum calcium.

Adverse reactions

The most common adverse reactions in clinical trials included: arthralgia, pain, and nausea. Other adverse reactions include dizziness and leg cramps.

Use in specific populations

Pregnancy and Lactation

There is no available data on BONSITY use in pregnant women. Consider discontinuing when pregnancy is recognized.

It is not known whether teriparatide is excreted in human milk, affects human milk production, or has effects on the breastfed infant. Breastfeeding is not recommended.

For additional safety information, please see the full Prescribing Information, including Medication Guide, and full User Manual that accompanies the delivery device.

You are encouraged to report negative side effects of prescription drugs to Alvogen at 1-866-770-3024 or the FDA at www.fda.gov/medwatch, or call 1-800-FDA-1088.

References:

  1. Data on file. Alvogen, Inc.
  2. BONSITY® [prescribing information]. Morristown, NJ: Alvogen, Inc.

Contact

For questions regarding BONSITY, including insurance coverage:

For medical questions or to report adverse events:

Build new bone with
BONSITY teriparatide injection logo
BONSITY® is a registered trademark of Pfenex, Inc.
All other trademarks are the property of their respective owners.
© 2025 Alvogen. All rights reserved.
BON-WWW-2025  06/25